Siglec-9-neutralizing antibodies
US11623954B2 · kind B2 · utility
0Cited by
4References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 9, 2018 |
| Grant date | Apr 11, 2023 |
| Priority date | — |
| Expiry date | Jan 30, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.